Skip to main content
Press Enter
BASF offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry, ensuring the needs of our partners are always met. Every step of biopharmaceutical manufacturing requires high-quality raw materials delivered through a transparent, sustainable supply chain. BASF Biopharma Ingredients is committed to meeting your requirements for every ingredient we supply to the biologics industry. At BASF, we create excipients that are safe, effective, and convenient for your customers. Whether you’re developing orally disintegrating formulations that require taste-masking or modified release tablets, BASF has ingredients to deliver the precision you need, every time. At BASF, we offer a comprehensive range of cutting-edge solubilization polymers, and have an unparalleled understanding of the corresponding process technologies. BASF offers an unparalleled portfolio of excipients for topical formulations, enabling you with the tools to overcome formulation challenges. With products based on over 150 years of industry experience, BASF is committed to maintaining the highest level of quality across the product spectrum.
View in MyProductWorld
MyProductWorld Your Product Assistant
Illustration of MyProductWorld Representative
View documentation
RegXcellence® Your Virtual Quality & Regulatory Assistant
Illustration of RegXcellence Representative
Try it in a Formulation
ZoomLab™ Your Virtual Formulation Assistant

Save time and money. Instantly predict your next formulation now!

Benefits

  • K85EE omega-3-acid ethyl esters contains a minimum 43% EPA and 34% DHA and minimum 90% of total omega-3-acid ethyl esters
  • Chemically Eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester, this API complies with the European pharmacopoeia (Ph Eur.), US pharmacopoeia (USP)
  • FDA Draft Guidance on Omega-3-Acid Ethyl Esters. K85 EE is documented in a CEP and a US-DMF
  • As an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL hypertriglyceridemia (HTG). Additionally, in Europe and ROW approved for post-MI – after myocardial infarction
  • Long history of production and delivery of Omacor®/Lovaza™, the first FDA and EU approved omega-3 based prescription drug

Functionalities

Cardiovascular Health

Technical Overview

Compendial Name

Region of Manufacture

Norway

Pack Size

See all technical details about Omega-3-Acid Ethyl Esters (K85EE) for US market

MyProductWorld is your resource for technical detail about BASF products